Trial Profile
A Phase 1 randomised, double-blind, placebo-controlled study to assess the safety and tolerability of Bacteroides thetaiotaomicron in young people aged 16 to 18 years with stable Crohn's disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Bacteroides thetaiotaomicron (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; First in man
- Sponsors 4D Pharma PLC
- 16 May 2019 Results presented in the 4D Pharma PLC media release.
- 16 May 2019 According to a 4D Pharma PLC media release, the company has announced the top-line results from this study.
- 15 May 2019 According to a 4D Pharma PLC media release, data from this trial will be presented at the 52nd Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) on 7 June 2019.